These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2960431)

  • 1. D-1 and D-2 agonists in Parkinson's disease.
    Lieberman AN; Goldstein M; Gopinathan G; Neophytides A
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):466-73. PubMed ID: 2960431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.
    Markham A; Benfield P
    CNS Drugs; 1997 Apr; 7(4):328-40. PubMed ID: 27520755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of levodopa failures: the use of dopamine agonists.
    Lieberman AN; Gopinathan G; Neophytides A; Goldstein M
    Clin Neuropharmacol; 1986; 9 Suppl 2():S9-21. PubMed ID: 3297319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of pergolide and mesulergine.
    Lieberman AN; Gopinathan G; Neophytides A
    Eur Neurol; 1986; 25(2):86-90. PubMed ID: 3948891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of pergolide and lisuride, two experimental dopamine agonists, in patients with advanced Parkinson disease.
    Lieberman AN; Leibowitz M; Gopinathan G; Walker R; Hiesiger E; Nelson J; Goldstein M
    Am J Med Sci; 1985 Sep; 290(3):102-6. PubMed ID: 4050844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease.
    Lieberman A; Chin L; Baumann G
    Clin Neuropharmacol; 1988 Jun; 11(3):191-200. PubMed ID: 2900065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bromocriptine in Parkinson disease.
    Lieberman AN; Goldstein M
    Pharmacol Rev; 1985 Jun; 37(2):217-27. PubMed ID: 3901046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
    Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease.
    Radad K; Gille G; Rausch WD
    Pharmacol Rep; 2005; 57(6):701-12. PubMed ID: 16382188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine agonists as primary treatment in Parkinson's disease.
    Rinne UK
    Adv Neurol; 1987; 45():519-23. PubMed ID: 3103394
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085.
    Schneider E; Hubener K; Fischer PA
    Neurology; 1983 Apr; 33(4):468-72. PubMed ID: 6682193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine agonists and Parkinson's disease.
    Burton K; Calne DB
    Clin Neurol Neurosurg; 1984; 86(3):172-7. PubMed ID: 6091965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should dopamine agonists be given early or late? A review of nine years experience with bromocriptine.
    Lieberman AN; Gopinathan G; Hassouri H; Neophytides A; Goldstein M
    Can J Neurol Sci; 1984 Feb; 11(1 Suppl):233-7. PubMed ID: 6713322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Parkinson's disease with dopamine agonists: a review.
    Lieberman A; Neophytides A; Kupersmith M; Casson I; Durso R; Foo SH; Khayali M; Tartaro T; Goldstein M
    Am J Med Sci; 1979; 278(1):65-76. PubMed ID: 39452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacology of Parkinson's disease: basic aspects and recent advances.
    Da Prada M; Keller HH; Pieri L; Kettler R; Haefely WE
    Experientia; 1984 Nov; 40(11):1165-72. PubMed ID: 6437857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pergolide and lisuride in advanced Parkinson's disease.
    Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Goldstein M
    Adv Neurol; 1984; 40():503-7. PubMed ID: 6695627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of pergolide, a potent dopamine agonist, in Parkinson's disease.
    Lieberman AN; Goldstein M; Neophytides A; Leibowitz M; Gopinathan G; Walker R; Pact V
    Clin Pharmacol Ther; 1982 Jul; 32(1):70-5. PubMed ID: 7083733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G;
    Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine agonists in Parkinson's disease.
    Calne DB; Burton K; Beckman J; Martin WR
    Can J Neurol Sci; 1984 Feb; 11(1 Suppl):221-4. PubMed ID: 6231979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.